

Measuring VWF elongation in shear flow. In shear flow, the fluid farther from the wall moves faster, as illustrated by the gray arrows. Free VWF moves during image acquisition, so the image forms a blur that is longer than the length of the protein, and depends on the distance of VWF from the wall. Surface-attached VWF does not move with the flow, so any elongation in the image reflects actual protein stretching. Professional illustration by Somersault18:24.

active conformation of the GPIIb-binding domain of VWF, whereas others do not,⁹ suggesting that 1 approach to creating safer blood-contacting devices is to control surface chemistry. However, it is also possible that polymers tethered to surfaces stretch more in the flow. Although, in a study by Fu et al,² the elongation of surface-tethered VWF inflow was intermediate between that of free VWF in previous contradictory studies,⁵⁻⁷ it was significantly more than the elongation of free VWF measured by Bergal et al (see figure). Moreover, a common model for the VWF polymer fits both the Bergal et al-free VWF and Fu et al-tethered VWF extensive data, demonstrating that surface tethering alone is sufficient to increase VWF elongation. Together, this supports the notion that it is important to design blood-contacting devices that limit the shear flow at device surfaces.

Although this study focused on free VWF in shear flow, the methods used here should advance our ability to characterize a range of shear-dependent processes in circulating blood or other fluids. VWF can also bind to other VWF multimers or circulating platelets in flow, which is likely to alter shear-dependent VWF tension and elongation and thus contribute to hemostatic and thrombotic dysregulation in blood-contacting devices.

Certain bacteria that cause infective endocarditis bind to immobilized platelets in a shear-dependent manner,¹⁰ suggesting that this may also occur in circulating blood, which would likely impact bacterial transport to the endocardium. As illustrated by these examples, binding is a critical factor in many shear-enhanced processes; therefore, the PULSIS method to measure particle size accurately at very high flow rates could be especially powerful if shown to be compatible with dual fluorescent labeling.

Conflict-of-interest disclosure: The author declares no competing financial interests. ■

REFERENCES

1. Bergal HT, Jiang Y, Yang D, Springer TA, Wong WP. Conformation of von Willebrand factor in shear flow revealed with

stroboscopic single-molecule imaging. *Blood*. 2022;140(23):2490-2499.

2. Fu H, Jiang Y, Yang D, et al. Flow-induced elongation of von Willebrand factor precedes tension-dependent activation. *Nat Commun*. 2017;8(1):324.
3. Yago T, Lou J, Wu T, et al. Platelet glycoprotein Iba1 forms catch bonds with human WT vWF but not with type 2B von Willebrand disease vWF. *J Clin Invest*. 2008;118(9):3195-3207.
4. Zhang X, Halvorsen K, Zhang CZ, Wong WP, Springer TA. Mechanoenzymatic cleavage of the ultralarge vascular protein von Willebrand factor. *Science*. 2009;324(5932):1330-1334.
5. Schneider SW, Nuschke S, Wixforth A, et al. Shear-induced unfolding triggers adhesion of von Willebrand factor fibers. *Proc Natl Acad Sci U S A*. 2007;104(19):7899-7903.
6. Shankaran H, Alexandridis P, Neelamegham S. Aspects of hydrodynamic shear regulating shear-induced platelet activation and self-association of von Willebrand factor in suspension. *Blood*. 2003;101(7):2637-2645.
7. Vergauwe RMA, Uji-I H, de Ceunynck K, et al. Shear-stress-induced conformational changes of von Willebrand factor in a water-glycerol mixture observed with single molecule microscopy. *J Phys Chem B*. 2014;118(21):5660-5669.
8. Zheng X, Silber-Li Z. The influence of Saffman lift force on nanoparticle concentration distribution near a wall. *Appl Phys Lett*. 2009;95:124105.
9. Tronic EH, Yakovenko O, Weidner T, et al. Differential surface activation of the A1 domain of von Willebrand factor. *Biointerphases*. 2016;11(2):29803.
10. Yakovenko O, Nunez J, Bensing B, et al. Serine-rich repeat adhesins mediate shear-enhanced streptococcal binding to platelets. *Infect Immun*. 2018;86(6):e00160-18.

<https://doi.org/10.1182/blood.2022018233>

© 2022 by The American Society of Hematology

TRANSPLANTATION

Comment on Vallet et al, page 2500

What a “harmless” antibiotic can teach us about GVL

Katie Maurer and Robert J. Soiffer | Dana-Farber Cancer Institute

In medicine, actions taken in good faith may lead to manifold unintended consequences, including off-target effects and unexpected toxicities of medications typically considered safe. In this issue of *Blood*, Vallet et al

demonstrate that allogeneic hematopoietic stem cell transplant (HSCT) patients receiving azithromycin have alterations in T cell metabolism and increased T cell exhaustion (see figure), potentially underlying the loss of graft-versus-leukemia (GVL) activity and increased risk of disease relapse observed in the ALLOZITHRO trial.^{1,2}


Azithromycin is the second most prescribed antibiotic in the United States.³ In addition to its antibacterial properties, the antiinflammatory functions of azithromycin are commonly used to prevent exacerbations of chronic obstructive pulmonary disease and are associated with improved survival after lung transplantation.⁴ Chronic graft-versus-host disease (GVHD) of the lung is a debilitating and often fatal complication for HSCT patients. In single-arm studies, combination therapy including azithromycin had shown promise in ameliorating progression of bronchiolitis obliterans syndrome (BOS), a manifestation of chronic lung GVHD.^{5,6} Limiting inflammation to prevent GVHD after HSCT seems desirable *prima facie*, particularly with the use of such a common and “safe” medication as azithromycin. However, previous *in vitro* work implicated azithromycin in inhibiting proliferation and proinflammatory cytokine production of CD4⁺ T cells.⁷ The ALLOZITHRO trial evaluating azithromycin for prevention of BOS disappointingly did not demonstrate a reduction in lung GVHD but alarmingly did identify a higher rate of leukemia

relapse among patients receiving azithromycin.² These data are a sobering reminder that seemingly benign interventions may have unwanted and even fatal consequences.

Using patient samples obtained during the ALLOZITHRO trial, Vallet et al sought to understand mechanisms through which azithromycin might promote disease recurrence. The authors performed complementary flow cytometric, mass cytometric, and single-cell transcriptional analyses on peripheral blood, as well as metabolomic analysis, to construct an integrated assessment of cellular composition and pathways affected by azithromycin administration. They found that azithromycin treatment led to an actual reduction in T cell number. Moreover, these T cells were skewed toward increased T regulatory, central and effector memory T_H2 CD4⁺, and exhausted CD8⁺ central memory (PD-1, TIGIT, and TOX expressing) cells with a concomitant decrease in cytotoxic (Granzyme B expressing) CD8⁺ central memory cells. Analysis of plasma and intracellular metabolic pathways demonstrated lower glycolytic activity,

which is central to T cell activation and effector functions hypothesized to be the basis for GVL. This finding was confirmed *in vitro*, with inhibition of glycolysis observed in T cells cultured with azithromycin. Additional *in vitro* work demonstrated that azithromycin treatment directly led to inhibition of T cell proliferation, which was exacerbated by the addition of cyclosporine, suggesting an additive effect of azithromycin with GVHD prophylaxis. These data advance our understanding of possible mechanisms of relapse after HSCT through T cell exhaustion and ineffective cytotoxic function that may be exacerbated by exposure to azithromycin. Future studies should leverage these and other advanced technologies, such as spatial and interactional analysis at single-cell resolution to gain a deeper understanding of intra- and intercellular crosstalk driving both relapse and GVL. Although relapse is likely multifactorial, exhausted or immunoregulatory T cells are likely candidates as drivers. Preclinical studies of graft selection/manipulation to reduce or reverse exhaustion and promote antitumor T cell activity will further elucidate the precise cell subsets and pathways responsible for loss of GVL and identify novel therapeutic targets.

Relapse remains the major cause of failure after allogeneic transplantation for malignant disease.⁸ Although GVL mediated by donor T cells has been broadly accepted as a primary driver of antitumor activity for decades, the underlying mechanisms remain surprisingly poorly understood.⁹ GVL and GVHD are often thought of as 2 sides of the same coin: Proinflammatory T cell activity promotes GVL and prevents relapse, but overactivity of donor T cells causes deleterious inflammation leading to GVHD. Various attempts at manipulating HSCT grafts to promote GVL and reduce GVHD have been made but are not yet specific enough to separate these processes. For example, HSCT with *in vivo* or *ex vivo* T cell depletion (TCD) has been used successfully for improved GVHD prevention, but some studies of TCD have shown higher relapse rates, particularly for chronic myelogenous leukemia.¹⁰ These observations highlight the need for more sophisticated understanding of the precise molecular mechanisms and T cell functional subsets responsible



Azithromycin treatment leads to more T cell exhaustion, which may impair GVL and promote relapse.

for mediating GVL and GVHD. Integrating next-generation technologies for transcriptional, metabolomic, and pathway analysis improves characterization of the diverse immune subsets at a single-cell level beyond traditional immunophenotyping.

Fine-tuning the balance of pro- and antiinflammatory factors to promote GVL while limiting GVHD is the “holy grail” of HSCT. Altogether, Vallet et al provide compelling evidence for a role of azithromycin in modulating T cell activity after HSCT to promote relapse and underscore how much remains undiscovered in understanding the complex interplay of therapies, cells, and metabolic pathways driving relapse and GVL.

Conflict-of-interest disclosure: R.J.S. is a consultant for Vor Biopharma, Neovii, CSL Behring, Bluesphere Bio, Cugene, and Jasper; on the Data Safety Monitoring Board of Juno Therapeutics/BMS/Celgene USA; and on the Board of Directors of NMPD Be the Match, USA. K.M. declares no competing financial interests. ■

REFERENCES

1. Vallet N, Le Grand S, Bondeelle L, et al. Azithromycin promotes relapse by disrupting immune and metabolic networks after allogeneic stem cell transplantation. *Blood*. 2022;140(23):2500-2513.
2. Bergeron A, Chevret S, Granata A, et al. Effect of azithromycin on airflow decline-free survival after allogeneic hematopoietic stem cell transplant: the ALLOZITHRO randomized clinical trial. *JAMA*. 2017;318(6):557-566.
3. Hicks LA, Bartoces MG, Roberts RM, et al. US outpatient antibiotic prescribing variation according to geography, patient population, and provider specialty in 2011. *Clin Infect Dis*. 2015;60(9):1308-1316.
4. Li D, Duan Q, Weinkauff J, et al. Azithromycin prophylaxis after lung transplantation is associated with improved overall survival. *J Heart Lung Transplant*. 2020;39(12):1426-1434.
5. Williams KM, Cheng GS, Pusic I, et al. Fluticasone, azithromycin, and montelukast treatment for new-onset bronchiolitis obliterans syndrome after hematopoietic cell transplantation. *Biol Blood Marrow Transplant*. 2016;22(4):710-716.
6. Penack O, Marchetti M, Ruutu T, et al. Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation. *Lancet Haematol*. 2020;7(2):e157-e167.
7. Ansari AW, Sharif-Askari FS, Jayakumar MN, et al. Azithromycin differentially alters TCR-activated helper T cell subset phenotype and effector function. *Front Immunol*. 2020;11:556579.
8. Horowitz M, Schreiber H, Elder A, et al. Epidemiology and biology of relapse after stem cell transplantation. *Bone Marrow Transplant*. 2018;53(11):1379-1389.
9. Horowitz MM, Gale RP, Sondel PM, et al. Graft-versus-leukemia reactions after bone marrow transplantation. *Blood*. 1990;75(3):555-562.
10. Goldman JM, Gale RP, Horowitz MM, et al. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion. *Ann Intern Med*. 1988;108(6):806-814.

<https://doi.org/10.1182/blood.2022018225>

© 2022 by The American Society of Hematology